{
  "docId": "019de517-44b3-71b5-8a8d-243b41bb1797",
  "docSlug": "c77cf9536b998c2f906519be4212f807",
  "documentTitle": "GH Research | Investor Presentation Deck | 30 slides",
  "authorId": "gh-research",
  "authorName": "GH Research",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 30,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/25",
  "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797",
  "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json",
  "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.619,
        "w": 0.866,
        "x": 0.068,
        "y": 0.194
      },
      "kind": "diagram",
      "text": "Double-Blind Phase\nOpen-label Extension Phase (OLE)\nGH001 IDR\nn=80\nRandomization 1:1\nPlacebo IDR\nUp to 5 GH001 IDRs may be administered during the OLE pro re nata (PRN), based on specific re-treatment criteria\nPRN\nScheduled Visit D0 D1 D7 D14 M1 M2 M3 M4 M5 M6\nPrimary Endpoint ΔMADRS\n(per FDA guidance for rapid-acting antidepressants*)",
      "attrs": {},
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05d7cfae-41a2-45af-9409-e1109b3d6d01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.894,
        "x": 0.054,
        "y": 0.857
      },
      "kind": "source-note",
      "text": "The bold solid lines indicate the fixed duration of 7 days (± 1 day) after an IDR with visits on D0, D1 and D7. The bold dotted line indicates the variable duration until a potential GH001 IDR in the OLE. The GH001 IDR consists of up to 3 increasing doses (6, 12, 18 mg) and the Placebo IDR consists of up to three placebo doses, to achieve a peak experience, given at a 1H interval. As in previously completed trials, the GH001-TRD-201 trial will be conducted under the supervision of a healthcare provider, but without any planned psychotherapeutic interventions before, during, or after dosing. IDR, Individualized Dosing Regimen; PRN, pro re nata (as needed); B, Baseline; H, Hour; D, Day; M, Month. *FDA draft guidance for industry \"Major Depressive Disorder: Developing Drugs for Treatment\"",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fb3cbcc-0871-471e-8341-f1e53041c9a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.76,
        "x": 0.071,
        "y": 0.101
      },
      "kind": "title",
      "text": "Design of Phase 2b Trial in TRD (GH001-TRD-201)",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdf0ef99-4842-4e89-a70e-4c7d2468d004",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e59b812c-5781-40d1-880d-5eb666da502e",
      "evidence": "The document emphasizes the limitations of current treatments and the potential of GH001",
      "position": 0,
      "objective": "Highlight the need for more effective depression treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa",
      "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions",
      "position": 1,
      "objective": "Explain why GH001 is a necessary solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}